SG11201811232XA - Treatment of amd using aav2 variant with aflibercept - Google Patents
Treatment of amd using aav2 variant with afliberceptInfo
- Publication number
- SG11201811232XA SG11201811232XA SG11201811232XA SG11201811232XA SG11201811232XA SG 11201811232X A SG11201811232X A SG 11201811232XA SG 11201811232X A SG11201811232X A SG 11201811232XA SG 11201811232X A SG11201811232X A SG 11201811232XA SG 11201811232X A SG11201811232X A SG 11201811232XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- amd
- suite
- publication
- aflibercept
- Prior art date
Links
- 229960002833 aflibercept Drugs 0.000 title abstract 3
- 108010081667 aflibercept Proteins 0.000 title abstract 3
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 3
- 208000002780 macular degeneration Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351234P | 2016-06-16 | 2016-06-16 | |
| PCT/US2017/038003 WO2017218974A2 (en) | 2016-06-16 | 2017-06-16 | Treatment of amd using aav2 variant with aflibercept |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811232XA true SG11201811232XA (en) | 2019-01-30 |
Family
ID=60663653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811232XA SG11201811232XA (en) | 2016-06-16 | 2017-06-16 | Treatment of amd using aav2 variant with aflibercept |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20190151409A1 (el) |
| EP (2) | EP3471780B1 (el) |
| JP (4) | JP6814822B2 (el) |
| KR (2) | KR20210021113A (el) |
| CN (2) | CN109641065A (el) |
| AU (2) | AU2017286673B2 (el) |
| BR (1) | BR112018076124A2 (el) |
| CA (1) | CA3027737A1 (el) |
| CY (1) | CY1123697T1 (el) |
| DK (1) | DK3471780T3 (el) |
| ES (1) | ES2840059T3 (el) |
| HR (1) | HRP20201842T1 (el) |
| HU (1) | HUE051953T2 (el) |
| IL (2) | IL263686B (el) |
| LT (1) | LT3471780T (el) |
| MX (2) | MX2018015512A (el) |
| PT (1) | PT3471780T (el) |
| RS (1) | RS61311B1 (el) |
| SG (1) | SG11201811232XA (el) |
| SI (1) | SI3471780T1 (el) |
| WO (1) | WO2017218974A2 (el) |
| ZA (1) | ZA201808538B (el) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015142941A1 (en) | 2014-03-17 | 2015-09-24 | Avalanche Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| IL254148B (en) | 2015-03-02 | 2022-09-01 | Adverum Biotechnologies Inc | Preparations and methods for intraocular delivery of polynucleotides to the retina |
| WO2018075798A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| BR112019019158A2 (pt) | 2017-03-17 | 2020-05-05 | Adverum Biotechnologies Inc | composições e métodos para expressão genética melhorada |
| CN107661492A (zh) * | 2017-08-31 | 2018-02-06 | 中山大学中山眼科中心 | Vegf‑b的新用途 |
| CN107537026A (zh) * | 2017-08-31 | 2018-01-05 | 中山大学中山眼科中心 | Vegf‑b的应用 |
| WO2019079494A1 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio, Inc. | TREATMENT OF OCULAR DISEASES AND METASTATIC COLON CANCER WITH A VEGF TRAP WITH HUMAN POST-TRANSLATIONAL MODIFICATION |
| BR112020010674A2 (pt) * | 2017-11-27 | 2020-11-10 | 4D Molecular Therapeutics Inc. | capsídeos de variante de vírus adeno-associado e uso para inibir a angiogênese |
| EP3727468A4 (en) | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR |
| WO2019198084A1 (en) * | 2018-04-12 | 2019-10-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-aging compositions and methods of use |
| EP3934698A1 (en) * | 2019-03-04 | 2022-01-12 | Adverum Biotechnologies, Inc. | Sequential intravitreal administration of aav gene therapy to contralateral eyes |
| EP4027983A1 (en) * | 2019-09-11 | 2022-07-20 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| CN114390928A (zh) * | 2019-09-11 | 2022-04-22 | 阿德夫拉姆生物技术股份有限公司 | 使用编码阿柏西普的aav2变体治疗眼新血管疾病的方法 |
| TWI819268B (zh) | 2020-01-16 | 2023-10-21 | 詹姆斯 Ｗ 希爾 | 藉由基因轉導改變眼睛顏色 |
| CN113952473A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| CN113817775B (zh) * | 2020-08-25 | 2023-02-17 | 南京吉迈生物技术有限公司 | 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用 |
| JP2021049374A (ja) * | 2020-12-09 | 2021-04-01 | 株式会社三洋物産 | 遊技機 |
| KR20240005764A (ko) * | 2021-04-27 | 2024-01-12 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 아플리베르셉트를 코딩하는 aav2 변이체를 사용하여 안구 질환을 치료하는 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102121355B1 (ko) * | 2011-04-22 | 2020-06-11 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 변이체 캡시드를 지니는 아데노-관련 바이러스 및 이의 사용 방법 |
| EP2846836B1 (en) * | 2012-05-07 | 2019-08-14 | Allergan, Inc. | Method of treating amd in patients refractory to anti-vegf therapy |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| KR20230152151A (ko) * | 2013-07-12 | 2023-11-02 | 이베릭 바이오, 인크. | 안과적 질환을 치료하거나 예방하기 위한 방법 |
| MX2016004736A (es) | 2013-10-18 | 2016-07-26 | Regeneron Pharma | Metodos y composiciones que comprenden una combinacion de un antagonista de vegf y un anticuerpo anti-ctla-4. |
| IL254148B (en) * | 2015-03-02 | 2022-09-01 | Adverum Biotechnologies Inc | Preparations and methods for intraocular delivery of polynucleotides to the retina |
-
2017
- 2017-06-16 EP EP17814223.8A patent/EP3471780B1/en active Active
- 2017-06-16 KR KR1020217004488A patent/KR20210021113A/ko not_active Application Discontinuation
- 2017-06-16 EP EP20196657.9A patent/EP3795181A1/en active Pending
- 2017-06-16 MX MX2018015512A patent/MX2018015512A/es unknown
- 2017-06-16 JP JP2018565845A patent/JP6814822B2/ja active Active
- 2017-06-16 SI SI201730553T patent/SI3471780T1/sl unknown
- 2017-06-16 RS RS20201517A patent/RS61311B1/sr unknown
- 2017-06-16 CA CA3027737A patent/CA3027737A1/en active Pending
- 2017-06-16 LT LTEP17814223.8T patent/LT3471780T/lt unknown
- 2017-06-16 HU HUE17814223A patent/HUE051953T2/hu unknown
- 2017-06-16 WO PCT/US2017/038003 patent/WO2017218974A2/en unknown
- 2017-06-16 KR KR1020197001023A patent/KR102218265B1/ko active IP Right Grant
- 2017-06-16 DK DK17814223.8T patent/DK3471780T3/da active
- 2017-06-16 SG SG11201811232XA patent/SG11201811232XA/en unknown
- 2017-06-16 ES ES17814223T patent/ES2840059T3/es active Active
- 2017-06-16 PT PT178142238T patent/PT3471780T/pt unknown
- 2017-06-16 AU AU2017286673A patent/AU2017286673B2/en active Active
- 2017-06-16 CN CN201780050283.2A patent/CN109641065A/zh active Pending
- 2017-06-16 BR BR112018076124A patent/BR112018076124A2/pt unknown
- 2017-06-16 CN CN202311530329.4A patent/CN117531025A/zh active Pending
-
2018
- 2018-12-12 US US16/218,353 patent/US20190151409A1/en not_active Abandoned
- 2018-12-13 IL IL263686A patent/IL263686B/en active IP Right Grant
- 2018-12-13 MX MX2022004786A patent/MX2022004786A/es unknown
- 2018-12-18 ZA ZA2018/08538A patent/ZA201808538B/en unknown
-
2020
- 2020-09-16 JP JP2020155475A patent/JP2020203941A/ja not_active Withdrawn
- 2020-11-19 HR HRP20201842TT patent/HRP20201842T1/hr unknown
- 2020-11-30 CY CY20201101133T patent/CY1123697T1/el unknown
-
2021
- 2021-01-03 IL IL279919A patent/IL279919A/en unknown
- 2021-09-01 AU AU2021225178A patent/AU2021225178A1/en active Pending
- 2021-09-20 US US17/479,968 patent/US20220265740A1/en active Pending
-
2022
- 2022-07-15 JP JP2022113865A patent/JP2022137244A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095160A patent/JP2024113193A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201901364VA (en) | Engineered target specific nucleases | |
| SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201901221YA (en) | Methods for detecting aav | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
| SG11201909011PA (en) | Niraparib compositions |